32 results on '"Yañez, Eduardo"'
Search Results
2. Enhancing oxidative stability of biodiesel using fruit peel waste extracts blend: Comparison of predictive modelling via RSM and ANN techniques
3. Implementation of Sentiment Analysis in Chatbots in Spanish to Detect Signs of Mental Health Problems
4. CHRONOS-4: phase 3 study of copanlisib plus rituximab–based immunochemotherapy in relapsed indolent B-cell lymphoma
5. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial
6. Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
7. Serena Dyer Shopping and the Senses, 1800-1970. A Sensory History of Retail and Consumption. Charm: Palgrave Macmillan, 2022. 216 pp.
8. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial
9. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
10. #1121 KEYNOTE-826: final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer
11. #67 Pembrolizumab + chemotherapy for first-line treatment of patients with persistent, recurrent, or metastatic cervical cancer: bevacizumab subgroup analysis based on protocol-specified final overall survival results of KEYNOTE-826
12. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
13. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.
14. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients
15. Abstract A32: Copanlisib plus rituximab vs placebo plus rituximab in patients with follicular lymphoma: 1-year follow-up of the Phase III, randomized CHRONOS-3 trial
16. FLORA-5/GOG3035: Frontline chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] versus chemotherapy (paclitaxel-carboplatin-placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double-blind, placebo-controlled, global, multinational study.
17. Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826.
18. 739P Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trial
19. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
20. Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Copanlisib Plus Rituximab with Placebo Plus Rituximab
21. Abstract CT001: CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL)
22. Pegathor Lymphoma, a Phase 2 Study of SAR444245 As a Monotherapy or in Combination with Pembrolizumab for the Treatment of Adults and Adolescents with Relapsed or Refractory B Cell Lymphoma
23. ¿En qué va la gestión participativa local?
24. Deformable orthogonal grids: lemniscates
25. KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
26. Preoperative Chemoradiotherapy in the Treatment of Gallbladder Cancer
27. Model based simulation for survey planning and optimization
28. [Carta de Eduardo Yañez a Benito Pérez Galdós (26 de septiembre de 1908)]
29. [Carta de Eduardo Yañez a Benito Pérez Galdós (7 de noviembre de 1908)]
30. Crioconcentració de fluids alimentaris: una tecnologia emergent?
31. Leite sem lactose como agente encapsulante de probiótico pelo método de spray drying e seu comportamento em processos de crioconcentração
32. Desempenho do leite de cabra submetido aos processos de nanofiltração e crioconcentração em blocos com descongelamento gravitacional e a vácuo
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.